IQVIA Holdings, IncNYSE: IQV
Health Care · Life Sciences Tools & Services
$171.01
-1.25%
Vol: 1.8M
Research Digest
Wednesday, May 20, 2026
IQVIA expanded Kexing Biopharm AI biosimilars deal May 14 and authorized additional $2B buyback after Q1 beat.
IQVIA on May 14, 2026 announced an expansion of its strategic collaboration with Kexing Biopharm, integrating IQVIA's AI capabilities to support a multi-product biosimilar program across clinical development, regulatory strategy, analytics, and commercialization for international markets. Q1 2026 results (May 5) beat with EPS of $2.90 vs $2.85 estimate and revenue of $4.15B (up 8.4% YoY), with Commercial Solutions revenue climbing 11.6% to $1,754M and R&D Solutions up 6.2% to $2,397M. Adjusted EBITDA rose 5.5% to $932M (22.5% margin). FY26 guidance was raised: revenue $17.15B-$17.35B, adjusted EBITDA $3.975B-$4.025B, adjusted EPS $12.65-$12.95. The board authorized an additional $2B buyback, taking remaining authorization to $3.2B. Stock dropped 4.9% post-earnings to $152.98, but 16 analysts maintain a "Strong Buy" with a $227.13 average target.
Previous Market Intelligence
13 daysMay 19IQVIA expands AI-driven biosimilars collaboration with Kexing Biopharm on May 14 following Q1 beat and $2B buyback authorizationPositive▶
On May 14, 2026, IQVIA announced an expansion of its collaboration with Kexing Biopharm, aligning clinical development, regulatory strategy, analytics, and commercialization to support Kexing's multi-product biosimilar program for international markets using IQVIA's AI capabilities for faster trials. Q1 2026 results (May 5) delivered revenue of $4.15B (up 8.4% YoY) and adjusted diluted EPS of $2.90, beating estimates; Commercial Solutions grew 11.6% YoY and R&D Solutions grew 6.2%. The board authorized an additional $2 billion in share buybacks, bringing remaining authorization to $3.2B. Management raised FY2026 adjusted diluted EPS guidance to a $12.65-$12.95 range. Consensus among 16 analysts is Strong Buy with an average 12-month price target of $227.13. Risk: R&D Solutions growth is markedly slower than Commercial Solutions, and adjusted EBITDA margin contraction warrants monitoring.
May 18IQVIA expands Kexing Biopharm AI biosimilars collaboration on May 14, 2026, after a $2B buyback authorization and Q1 beat that raised FY26 EPS guide to $12.65-$12.95.Positive▶
IQVIA announced on May 14, 2026 an expansion of its collaboration with Kexing Biopharm, aligning clinical development, regulatory strategy, analytics and commercialization for Kexing's multi-product biosimilar program and embedding IQVIA's AI capabilities for faster trials. The deal follows a strong Q1 2026 print on May 5 where adjusted EPS of $2.90 beat the $2.85 estimate and revenue of $4.151B beat by ~$10M, prompting management to raise FY26 guidance to revenue of $17.15B-$17.35B, adjusted EBITDA of $3.975B-$4.025B and adjusted diluted EPS of $12.65-$12.95. Commercial Solutions grew 11.6% YoY to $1.754B, outpacing R&D Solutions at 6.2% growth to $2.397B. Q1 free cash flow was $491M, up 15% from $426M a year ago. On May 7, IQVIA expanded its share repurchase authorization by an additional $2 billion.
May 15IQVIA up 12.8% after Q1 2026 beat, raised guidance and $2B incremental buyback authorizationPositive▶
IQVIA reported Q1 2026 EPS of $2.90, beating $2.85 consensus, on record revenue of $4.151B (+~6% YoY) on May 5, 2026. The company raised full-year 2026 guidance to $17.15B-$17.35B revenue, adjusted EBITDA of $3.975B-$4.025B and adjusted EPS of $12.65-$12.95. The board authorized an additional $2.0B share repurchase, bringing total available authorization to $3.2B and lifetime program to $15.73B. Commercial Solutions revenue rose 11.6% YoY to $1.754B with Research & Development Solutions up 6.2% to $2.397B. Free cash flow was $491M, up 15%. Shares are up 12.8% post-earnings. Consensus rating is Strong Buy across 16 analysts with 12-month price target of $227.13 implying about 27% upside.
May 14IQVIA up 12.8% after Q1 2026 beat with $4.15B revenue and $2B share repurchase authorization expansionPositive▶
IQVIA reported Q1 2026 revenue of $4.151B and adjusted EPS of $2.90, beating expectations on May 5, with Commercial Solutions revenue up 11.6% YoY to $1.75B. The company raised full-year 2026 guidance to revenue of $17.15-$17.35B and adjusted EPS of $12.65-$12.95. On May 7, the board authorized an additional $2B share repurchase, bringing total remaining authorization to $3.2B. Free cash flow was $491M, up 15% YoY. CFO Mike Fedock presented at Bank of America Healthcare Conference on May 13. The company is also expanding its AI biosimilar collaboration with Kexing Biopharm.
May 13IQVIA shares jumped 12.8% after Q1 2026 beat (EPS $2.90), raised FY guidance, and $2.0B buyback authorization boost.Positive▶
IQVIA reported Q1 2026 revenue of $4.151B and adjusted EPS of $2.90, beating Wall Street expectations on May 5. Commercial Solutions grew 11.6% YoY to $1.754B (8.5% constant currency) outpacing R&D Solutions at 6.2% growth. The company raised full-year guidance to revenue of $17.15-17.35B, adjusted EBITDA of $3.975-4.025B and adjusted EPS of $12.65-12.95. Share buyback authorization expanded by $2.0B to a total $15.73B program. CFO Mike Fedock presented at the BofA Health Care Conference May 13. Stock up 12.8% post-beat. Risk: $34.2B backlog with concerns over slower organic growth and longer trial durations.
May 12IQVIA Holdings jumped 12.8% after Q1 2026 beat and Board authorized an additional $2 billion share repurchase on May 7, 2026.Positive▶
IQVIA reported Q1 2026 results on May 5, with revenue up 8.4% YoY to $4.15 billion (beating $4.14B estimate) and EPS of $2.90 (beating $2.85 estimate). Net income was $274 million. The company reaffirmed full-year 2026 revenue guidance of $17.15B-$17.35B. On May 7, the Board authorized an additional $2 billion share repurchase, bringing total remaining authorization to $3.2 billion. The stock rose 12.8% following the beat and expanded buyback. CFO Mike Fedock presented at the Bank of America Health Care Conference in Las Vegas on May 13. According to 16 analysts, the average rating for IQV is Strong Buy with a 12-month price target of $227.13, representing 27.09% upside.
May 11IQVIA board approves additional $2B share repurchase on May 7 after strong Q1 beat raised FY EPS guidancePositive▶
On May 7, 2026, IQVIA's board authorized an additional $2 billion stock repurchase, bringing total remaining authorization to $3.2 billion. Q1 2026 revenue of $4.15B beat expectations (up 8.4% YoY reported, 6% constant currency) and adjusted EPS of $2.90 beat with 7.4% YoY growth, both exceeding high end of guidance. IQVIA raised full-year adjusted EPS guidance to $12.65-$12.95 with Q2 revenue guidance of $4.28-$4.34B and EPS $2.98-$3.08. Stock initially dropped 4.9% to $152.98 post-report but later surged 13% to $179. Multiple Buy ratings with PTs ranging $213-$240.
May 8IQVIA reports Q1 2026 revenue beat at $4.15B (up 8.4% YoY) with adjusted EPS of $2.90, board approves $2B additional buyback authorization bringing total to $3.2B.Positive▶
IQVIA exceeded expectations with Q1 2026 revenue of $4.151 billion, 8.4% higher year-over-year, and adjusted EPS of $2.90 surpassing estimates. Commercial Solutions organic revenue growth doubled while R&D Solutions tripled. The company board authorized an additional $2 billion share repurchase, bringing total remaining authorization to $3.2 billion. IQVIA also launched IQVIA.ai, a unified AI platform for life sciences organizations, and reported strong demand from clients seeking AI-enabled capabilities. Company reaffirmed full-year guidance and highlighted record-level client pipelines.
May 7IQVIA Holdings beat Q1 2026 earnings on May 5 with revenue of $4.15B (+8.4% YoY) and EPS of $2.90 vs. $2.82 forecast.Positive▶
IQVIA delivered Q1 2026 results exceeding expectations with organic revenue growth doubling in Commercial Solutions and tripling in R&D Solutions. The company launched IQVIA.ai, an AI platform with 192 agents deployed across 64 use cases used by 19 of top 20 pharma companies. Revenue reached $4.151B vs. $4.1B estimate and adjusted EBITDA climbed 5.5% to $932M. Stock surged 7.37% on the earnings beat. Full-year revenue guidance set at $17.25B.
May 6IQVIA Q1 2026 EPS $2.90 beats forecast of $2.82; revenue $4.151B exceeds $4.1B estimate; stock surged 7.37%Positive▶
IQVIA Holdings beat Q1 2026 expectations with EPS of $2.90 (vs. forecast $2.82) and revenue of $4.151B (vs. forecast $4.1B). Revenue rose 8.4% YoY, net income increased to $274M, and diluted EPS increased to $1.61 from $1.40. Stock surged 7.37% after earnings beat with strong revenue growth in Commercial Solutions, outperforming healthcare sector's 0.26% gain. Key driver: AI solutions and new drug launches. IQVIA has 192 AI agents deployed covering 64 use cases; 19 of top 20 pharma companies use these AI agents. Secured multiyear agreements with Pfizer and Boehringer Ingelheim for AI-enabled data platforms. IQVIA supported 120+ obesity trials with 90K+ enrolled patients across FDA-approved GLP-1 therapies. Stock at $171.69 (down 23.8% YoY, 29.7% below $244.29 52-week high). Consensus Buy rating with upside potential.
May 5IQVIA reported Q1 2026 beats (EPS $2.90 vs $2.82 est, revenue $4.15B vs $4.10B est) but stock fell 5% as investors took profits despite raising FY guidance.Mixed▶
IQVIA Holdings beat Q1 2026 consensus with adjusted EPS of $2.90 (+2.9% beat) and revenue of $4.151B (+1.1% beat), but stock declined 5% premarket due to profit-taking. Company raised full-year 2026 adjusted EPS guidance to $12.80 midpoint and projects FY revenue of ~$17.25B. Major catalyst: launched IQVIA.ai in collaboration with NVIDIA, a unified agentic AI platform for life sciences workflows. Filed $3.14B ESOP shelf registration. Stock trades at $157.77 (YTD +30%, 90-day +31.8%, 30-day +8.9%) with significant valuation gap vs fair value estimates.
May 4IQVIA to announce Q1 2026 earnings May 5 after strong shareholder approval of new incentive plan and 2026 guidancePositive▶
IQVIA reported full-year 2026 guidance of $17.15B-$17.35B revenue, $3.98B-$4.03B adjusted EBITDA, and $12.55-$12.85 diluted EPS. Shareholders approved a new 2026 incentive stock plan and backed all directors at the annual meeting. The company will report Q1 2026 results before market open on May 5, with management hosting a conference call at 9:00 a.m. ET. Recent initiatives include launching IQVIA.ai Unified Agentic AI Platform in collaboration with Nvidia, with 19 of top 20 pharma companies already using IQVIA agents. The company beat analysts' revenue expectations last quarter with $4.36B in revenues, up 10.3% year-over-year.
May 1IQVIA launches IQVIA.ai with NVIDIA as Q1 earnings approach May 5Mixed▶
IQVIA Holdings announced the launch of IQVIA.ai, a unified agentic AI platform in collaboration with NVIDIA to support life sciences operations. Q1 2026 earnings scheduled for May 5 with expected EPS of $2.83, up 4.8% YoY. RBC Capital rated it Buy on April 15, while Evercore ISI lowered its PT to $185 from $225 on April 8. Stock declined 3.28% in the past day but up 27.79% over 90 days. Mixed analyst sentiment ahead of earnings.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| TMOTHERMO | $450.78 | +0.66% | -14.1% | 16.6x | 0.88 | $167.9B |
| DHRDANAHER | $170.92 | +2.32% | -12.5% | 18.8x | 0.84 | $121.1B |
| WATWATERS | $340.55 | +2.19% | +1.7% | 20.8x | 1.14 | $33.5B |
| AAGILENT | $113.32 | +2.49% | -5.9% | 17.3x | 1.22 | $32.2B |
| IQVIQVIA | $171.01 | -1.25% | -3.0% | 12.1x | 1.18 | $28.6B |
| MTDMETTLER | $1,079.54 | +2.74% | -18.3% | 21.1x | 1.31 | $21.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.